Pre-Conference Questions: Legal/Regulatory & Operational Considerations March 5, 2009.

Slides:



Advertisements
Similar presentations
Managing Compliance Productivity, Risk and Reputation Dalton Smart June 7, 2005 Executional Excellence.
Advertisements

Organizational Governance
Options appraisal, the business case & procurement
Life Science Services and Solutions
Child Safeguarding Standards
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
<<Date>><<SDLC Phase>>
Tax Risk Management Keeping Up with the Ever-Changing World of Corporate Tax March 27, 2007 Tax Services Bryan Slone March 27, 2007.
Training of master Trainers Workshop 10 – 15 November 2012 e-Services Design and Delivery Module IIX Emilio Bugli Innocenti.
AUDIT COMMITTEE FORUM TM ACF Roundtable IT Governance – what does it mean to you as an audit committee member July 2010 The AUDIT COMMITTEE FORUM TM is.
PwC Role of Internal Audit in Corporate Governance September 2010 Tumin Gültekin, Partner.
University of Southern California Enterprise Wide Information Systems Functionality and the Reference Model Instructor: Richard W. Vawter.
Access to Medicine Index 3 rd International Conference for Improving the Use of Medicines Poster 599 Tuesday 15 th November 2011.
BD / Pre SalesPMO Analysis / Requirements DesignDevelopmentTest / UATDeployMaintain PHASES ERP (AX) Implementation Lifecycle Sales/BD AX Solution.
© Huron Consulting Group Inc. All Rights Reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Corporate Social Responsibility- do we need a Statutory Instrument? Presented to the Zambia Alternative Mining Indaba conference- July 17, 2013 Sombo Chunda,
Business Analysis: A Business Unit Perspective International Institute of Business Analysis January 18, 2012.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
MassMEDIC February 26, 2010 Licensing and Compliance Presenter David L. Cavanaugh 60 State Street Boston, MA Pennsylvania Avenue, NW Washington,
OntarioMD’s EMR Maturity Model Advancing Optimization and Use Ontario College of Family Practice Annual Scientific Assembly Presented By: Darren Larsen,
September 2004 Copyright 2004 Antevorte Consulting, LLC Vision for Information Technology Service Delivery in Oregon David Rudawitz Antevorte Consulting,
OntarioMD’s EMR Maturity Model & Reporting Advancing Optimization and Use e-Health 2013 Accelerating Change Conference Presented By: Darren Larsen, MD,
© 2013 Cengage Learning. All Rights Reserved. 1 Part Four: Implementing Business Ethics in a Global Economy Chapter 9: Managing and Controlling Ethics.
CEB Corporate Leadership Council © 2013 The Corporate Executive Board Company. All Rights Reserved. 1 EMPLOYEE GUIDE: INTERACTING WITH EXTERNAL STAKEHOLDERS.
Corporate Governance in the Caribbean Environment “The Caribbean Corporate Governance Forum” Trevor E Blake General Manager – ECSE.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
Kathleen Donahue Damodar Rao Gummadapu Aspiring High. Above and Beyond, Our Journey to “Be the Best” Business Process Intelligence.
Diane Benson, CTSM Global Events Manager GE Healthcare, Medical Diagnostics Kathy Clarke Managing Partner SageRock Advisors, LLC.
© Huron Consulting Services LLC. All rights reserved. Aggregate Spend 101 March 5, 2009 L I F E S C I E N C E S A D V I S O R Y S E R V I C E S Manny Tzavlakis.
Implementing HIPAA State Budgets, Elections, and Policy Priorities National Association of Health Data Organizations 17 th Annual Meeting Atlanta, GA December.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Equal Opportunity for Women in the Workplace Agency Current and Future State CSA National Conference 6 th December 2011 Heather Gordon Education Manager.
The Quality Colloquium at Harvard University August 27, 2003 Patient Safety Organizational Readiness Assessment Tool Louis H. Diamond, MDBeverly A. Collins,
1 Leveraging the WTO/TBT Agreement New Delhi, India September 11, 2008 Elise Owen Representative for China and India Affairs American National Standards.
Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Pharmaceutical Regulatory and Compliance Congress.
Source: Deloitte Touche Tohmatsu GLOBALIZATION DIAGNOSTIC.
0 Best Practices in achieving Good Corporate Governance - a Practitioner’s Perspective “We have no lessons to give, only experience to share” June 2005.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Setting the Scene: The Role of Ethics and Compliance in the Biopharmaceutical Market.
Regulatory Impact Analysis (RIA) in OECD countries: a policy tool to manage the flow of regulation Regional Capacity-Building Seminar on “Drafting Legislation.
Customer Service & CRM Basics
The State of Partnering with States Aligning Forces for Quality National Meeting May 9, 2013 John M. Colmers Vice President Health Care Transformation.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
CAS Spring Meeting June 2007 Introduction to ERM …The Measurements, Quadrants, Tools, and Solutions Prof. Mark C. Vonnahme Fox Family Clinical Professor.
PwC National disclosure audio conference: Analysis of the revised Physician Payments Sunshine Act and state drug marketing laws February 10, 2009 “Where.
Financial Sector Development: Building Market Foundations Through International Codes And Standards Sherman G. Boone, Assistant Director Office of International.
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Overview of Huron and the International Medical Device Compliance Code Compendium The Second Annual Medical Device Regulatory, Reimbursement and Compliance.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Presentation Title Accountability and Transparency Heather Black, Managing Director, Economic Change CIC Insert your logo here.
©2012 THE ADVISORY BOARD COMPANY ADVISORY.COM Gaining Provider Feedback In February – March 2014, we administered a medical staff survey to employed &
Salesforce.com Migration Assessment with Microsoft Services Assess whether your current CRM implementation is the right solution for your current and future.
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
The Role of the HHS Office of Inspector General Summit on Disclosure, Transparency, and Aggregate Spend March 5, 2009 Mary E. Riordan, Office of Counsel.
MGMT 452 Corporate Social Responsibility
BU Commercial Director
SHARING CLINICAL DATA: Legal and Privacy Issues
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Beyond the DOJ: Compliance Best Practices in the Orthopedic Environment.
Private Sector Perspective: Key “Best Practices” that Strengthen Protection of Environment, Health and Safety while Facilitating Trade and Economic Development.
Lilly Grant Funding Disclosure May 27, 2008
OECD good practices for setting up an RIA system Regional Capacity-Building Seminar on Regulatory Impact Assessment Istanbul, Turkey 20 November 2007.
Analysis of the Proposed Sunshine Rule Implementation Issues
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
System Design and Acquisition
Presentation transcript:

Pre-Conference Questions: Legal/Regulatory & Operational Considerations March 5, 2009

Legal & Regulatory Considerations

Question #1  Virtually every department and level –Board –Officers/Management –Compliance –Legal –Medical Affairs –Sales and marketing –Regulatory/Clinical –Government Affairs –External Affairs/Communications –Etc. Who are the company stakeholders in the disclosure debate?

Question #2  Carefully examine assumptions regarding the business case for physician payment activities  Internal training on disclosure developments –Focus on benchmarking  Wargaming disclosure scenarios How do we prepare company leadership for disclosure?

Question #3  Examine currently available resources and proposals –Mechanisms for monitoring developing state requirements –Review of settlements and corporate integrity agreements –Peer company voluntary transparency initiatives –Developing federal legislation How do we benchmark our disclosure policies to prepare for future requirements?

Question #4  Conduct a targeted review to highlight potential vulnerabilities –Adequacy of internal controls and processes –Bona fide nature of relationships –Fair market value –Code compliance –Agreement adequacy –HCP obligations –Profile of thought leaders and related controversies How do we assess the potential impact of disclosure?

Question #5  Consider reforms, initiatives and voluntary disclosures to blunt impact  Prepare HCPs for the impact of disclosure  Prepare public responses to questions regarding specific relationships and areas of concern How do we defuse potential controversies resulting from disclosure?

Operational Considerations

Question #6 Determine Build vs. Buy for technical architecture Integrate Customer Master / Master Data Management Implement Aggregate Spend solution for reporting needs How do we determine the solutions that best fit our company?

Question #7 Create an “As-Is” state to determine blueprint of current systems and processes Develop “To-be” strategy to map optimized structure Build Roadmap to blueprint how to achieve next-generation state What are the steps to performing a gap analysis to determine strengths/weaknesses?

Determine which spend types are stored as data in specific systems Create policies and procedures to optimize the spend process Question #8 How can we map spend types to systems and processes?

Understand all of the circumstances under which healthcare entities are given payments, educations items, or other economic benefits. Determine where the spend is spread across the organization’s divisions and its external vendors. Question #9 How can my company identify all HCP/HCO touchpoints?

Gain an understanding of all systems and processes through which HCPs/ HCOs may receive value Capture all data necessary –ERP Systems –CRM / SFA Systems –T&E Applications –Grant Management tools –KOL Tracking –Clinical Activity solutions Question #10 What are the steps to understanding systems and processes?

Contacts Daniel A. Kracov Partner Arnold & Porter LLP 555 Twelfth Street, NW Washington DC – fax Paul Silver Managing Director Huron Consulting Group 6 Concourse Pkwy., Suite 2050 Atlanta, GA – Atlanta – New York – fax